Targeting of cancer neoantigens with donor-derived T cell receptor repertoires

Science

Volumn 352, Issue 6291, 2016, Pages 1337-1341

  Strønen, Erlend ^a,b   Toebes, Mireille ^c   Kelderman, Sander ^c   Van Buuren, Marit M ^c   Yang, Weiwen ^a,b   Van Rooij, Nienke ^c   Donia, Marco ^d   Böschen, Maxi Lu ^a,b   Lund Johansen, Fridtjof ^a,b   Olweus, Johanna ^a,b   Schumacher, Ton N ^c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER TESTIS ANTIGEN; CD20 ANTIGEN; HLA A2 ANTIGEN; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR BETA CHAIN; TUMOR ANTIGEN; EPITOPE; HLA-A*02:01 ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR; MESSENGER RNA;

ANTIGEN; BLOOD; CANCER; DISEASE TREATMENT; IMMUNE RESPONSE; MUTATION; TUMOR;

ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MEL 526 CELL LINE; MELANOMA CELL LINE; NORMAL HUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; BLOOD DONOR; GENETIC TRANSFECTION; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; MELANOMA; MUTATION; PRIMARY CELL CULTURE; TUMOR CELL CULTURE; TUMOR CELL LINE;

ANTIGENS, NEOPLASM; BLOOD DONORS; CELL LINE, TUMOR; EPITOPES, T-LYMPHOCYTE; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; MUTATION; PRIMARY CELL CULTURE; RECEPTORS, ANTIGEN, T-CELL; RNA, MESSENGER; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 84969764539     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.aaf2288     Document Type: Article

References (21)

1. S. A. Rosenberg, N. P. Restifo, Science 348, 62-68 (2015).
2. P. Sharma, J. P. Allison, Science 348, 56-61 (2015).
3. N. A. Rizvi et al., Science 348, 124-128 (2015).
4. E. M. Van Allen et al., Science 350, 207-211 (2015).
5. P. F. Robbins et al., Nat. Med. 19, 747-752 (2013).
6. N. van Rooij et al., J. Clin. Oncol. 31, e439-e442 (2013).
7. C. Linnemann et al., Nat. Med. 21, 81-85 (2015).
8. E. Tran et al., Science 350, 1387-1390 (2015).
9. E. Tran et al., Science 344, 641-645 (2014).
10. M. M. Gubin et al., Nature 515, 577-581 (2014).
11. H. Matsushita et al., Nature 482, 400-404 (2012).
12. M. Yadav et al., Nature 515, 572-576 (2014).
13. D. Mittal, M. M. Gubin, R. D. Schreiber, M. J. Smyth, Curr. Opin. Immunol. 27, 16-25 (2014).
14. B. M. Carreno et al., Science 348, 803-808 (2015).
15. Science Online.
16. I. W. Abrahamsen et al., Leukemia 24, 1901-1909 (2010).
17. T. Wölfel et al., Science 269, 1281-1284 (1995).
18. S. H. van der Burg, M. J. Visseren, R. M. Brandt, W. M. Kast, C. J. Melief, J. Immunol. 156, 3308-3314 (1996).
19. M. Harndahl et al., Eur. J. Immunol. 42, 1405-1416 (2012).
20. S. Kreiter et al., Nature 520, 692-696 (2015).
21. C. A. Klebanoff, S. A. Rosenberg, N. P. Restifo, Nat. Med. 22, 26-36 (2016).